- Pericyte Protective Agent
- Long-acting CGRP
- Long-acting Pramlintide
- Anti cell proliferative
LCT 0.047 Last updated EOD 18th January 2019
The following fact sheets provide a summary of our current business and research pipeline.
Long-acting calcitonin gene-related peptide (CGRP)
Migraine is a significant disabling condition with an unmet need for effective medicines. The World Heath Organisation compares severe migraine to dementia, quadriplegia and psychosis in terms of debilitation. There are safety and tolerability issues with current treatments as they are only partially effective and require frequent administration. Patients with other conditions such as depression and hypertension have their treatment options further restricted.
Research has identified a link between highter levels of the hormone calcitonin gene-related peptide (CGRP) and migraine. There is an emerging class of compounds that block the actions of CGRP, either antibodies or potentially longer-acting compounds that block CGRP receptors. Current receptor blockers in development with global pharmaceutical companies may have issues of side effects or toxicity.
Such issues my be avoided with novel peptide analogues of the CGRP structure that have been modified with a fatty acid group in order to increase half life in vivo. They present a range of new opportunities in migraine treatment.
Pre clinical studies of one such innovative compound, synthesised by Distinguished Professor Margaret Brimble's group at the University of Auckland, are under way at the university under lead investigators, Professors Kerry Loomes and Debbie Hay. Providing positive preclinical results we intend to continue to undertake clinical studies to demonstrate efficacy.
Positive clinical efficacy data would be used to out license the compound to a global pharmaceutical company to fully commercialise the compound.